Psych MEQs / SAQs · Psychotherapy — behavioural therapies
Exposure and response prevention for residual OCD on an SRI (MEQ)
FRANZCP/MRCPsych-style MEQ on ERP definition, technique, landmark evidence, fidelity, and SRI combination for residual OCD.
On this page
Study tools
Target exams
Model answer
Reveal model answerShowHide
(i) Definition and cycle. ERP/EX/RP is structured behavioural treatment in which the patient confronts obsession-evoking cues while systematically refraining from compulsions and other safety behaviours.[13] Obsessions/triggers raise distress; rituals (washing, checking, reassurance) reduce distress short-term; that negative reinforcement maintains OCD. ERP breaks the relief loop so expectancy violation and inhibitory safety learning can occur.[12][13]
(ii) Assessment and hierarchy. Confirm OCD dimensions, time occupied, covert rituals, depression/suicide risk, insight, and goals. Measure severity with Y-BOCS.[14] Inventory partner reassurance and any family cleaning/checking (accommodation). Build a collaborative hierarchy from moderate public-contact and bathroom-related tasks up to higher items (e.g. toilet seat contact) with explicit response-prevention rules (delayed/no washing; no reassurance questions; limited checking). Include imaginal items if harm fears co-travel with checking. Plan therapist-assisted then self-directed practices and partner coaching to stop accommodation.[13]
(iii) Evidence for offering EX/RP now. Foa 2005: EX/RP superior to clomipramine alone; combination not clearly better than EX/RP alone at 12 weeks in that design — supports behavioural treatment as a potent standalone and combined modality.[1] For SRI residual symptoms, Simpson 2008 showed EX/RP superior to stress management augmentation; Simpson 2013 showed EX/RP superior to risperidone and placebo augmentation — aligning with his preference to add EX/RP rather than antipsychotic first when acceptable and available.[2][3] Prior "supportive CBT" was not adequate-dose ERP, so he has not yet had an evidence-based behavioural trial.
(iv) Fidelity failures. Examples: no between-session exposures; allowing washing/reassurance after contact; therapist providing repeated safety reassurance; hierarchy never leaving mild items; sessions without agenda/homework review; family undoing practice at home.[13][15]
(v) Integration and step-up. Continue sertraline 200 mg oral daily if tolerated (monitor activation, sexual side effects, hyponatraemia risk, interactions) while delivering twice-weekly or high-homework weekly EX/RP; do not stop SRI solely to "start therapy."[2][3] Step up if non-response after adequate ERP dose/fidelity: intensify schedule/residential ERP, review SRI optimisation or clomipramine pathway, treat depression/risk, specialist OCRD service — not premature polypharmacy without behavioural trial.[13]
References7ShowHide
- [1]Foa EB, Liebowitz MR, Kozak MJ, et al. Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder Am J Psychiatry, 2005.PMID 15625214
- [2]Simpson HB, Foa EB, Liebowitz MR, et al. A randomized, controlled trial of cognitive-behavioral therapy for augmenting pharmacotherapy in obsessive-compulsive disorder Am J Psychiatry, 2008.PMID 18316422
- [3]Simpson HB, Foa EB, Liebowitz MR, et al. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial JAMA Psychiatry, 2013.PMID 24026523
- [12]Craske MG, Treanor M, Conway CC, et al. Maximizing exposure therapy: an inhibitory learning approach Behav Res Ther, 2014.PMID 24864005
- [13]Hezel DM, Simpson HB Exposure and response prevention for obsessive-compulsive disorder: A review and new directions Indian J Psychiatry, 2019.PMID 30745681
- [14]Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability Arch Gen Psychiatry, 1989.PMID 2684084
- [15]Wheaton MG, Galfalvy H, Steinman SA, et al. Patient adherence and treatment outcome with exposure and response prevention for OCD: Which components of adherence matter and who becomes adherent? Behav Res Ther, 2016.PMID 27497840